[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1105159T1 - (ιμιδαζολ-1-υλο-μεθυλο)-πυριδαζινη ως παρεμποδιστης υποδοχεα νμda - Google Patents

(ιμιδαζολ-1-υλο-μεθυλο)-πυριδαζινη ως παρεμποδιστης υποδοχεα νμda

Info

Publication number
CY1105159T1
CY1105159T1 CY20061101161T CY061101161T CY1105159T1 CY 1105159 T1 CY1105159 T1 CY 1105159T1 CY 20061101161 T CY20061101161 T CY 20061101161T CY 061101161 T CY061101161 T CY 061101161T CY 1105159 T1 CY1105159 T1 CY 1105159T1
Authority
CY
Cyprus
Prior art keywords
disease
neurodegeneration
compounds
nmda receptor
formula
Prior art date
Application number
CY20061101161T
Other languages
English (en)
Inventor
Bernd Buettelmann
Marie-Paule Heitz Neidhart
Georg Jaeschke
Emmanuel Pinard
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of CY1105159T1 publication Critical patent/CY1105159T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με ενώσεις του τύπου (I) όπου το Α είναι μια μη υποκατεστημένη κυκλική ομάδα και το R είναι υδρογόνο ή κατώτερη αλκυλομάδα και με φαρμακευτικώς αποδεκτά άλατα προσθήκης οξέος αυτών. Εχει δειχθεί ότι οι ενώσεις του τύπου ΙΑ και IB είναι καλοί ειδικοί παρεμποδιστές υποδοχέα NMDA υποτύπου NR-2B. Στις πιθανές θεραπευτικές ενδείξεις για τις ενώσεις αυτές περιλαμβάνονται οι οξείες μορφές νευροεκφυλισμού προκαλούμενου, π.χ., από εγκεφαλικό επεισόδιο και εγκεφαλικό τραύμα, και χρόνιες μορφές νευροεκφυλισμού όπως η νόσος Alzheimer, η νόσος Parkinson, η νόσος Huntington, η ALS (πλάγια μυατροφική σκλήρυνση) και ο νευροεκφυλισμός ο οποίος σχετίζεται με βακτηριακές ή ιικές λοιμώξεις και επίσης, η κατάθλιψη και ο χρόνιος ή οξύς πόνος.
CY20061101161T 2002-05-16 2006-08-22 (ιμιδαζολ-1-υλο-μεθυλο)-πυριδαζινη ως παρεμποδιστης υποδοχεα νμda CY1105159T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02010217 2002-05-16
EP03752750A EP1506190B1 (en) 2002-05-16 2003-05-16 (imidazol-1-yl-methyl)-pyridazine as nmda receptor blocker
PCT/EP2003/005151 WO2003097637A1 (en) 2002-05-16 2003-05-16 (imidazol-1-yl-methyl)-pyridazine as nmda receptor blocker

Publications (1)

Publication Number Publication Date
CY1105159T1 true CY1105159T1 (el) 2009-11-04

Family

ID=29433072

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101161T CY1105159T1 (el) 2002-05-16 2006-08-22 (ιμιδαζολ-1-υλο-μεθυλο)-πυριδαζινη ως παρεμποδιστης υποδοχεα νμda

Country Status (31)

Country Link
US (1) US7005432B2 (el)
EP (1) EP1506190B1 (el)
JP (1) JP4267569B2 (el)
KR (1) KR100632868B1 (el)
CN (1) CN1312151C (el)
AR (1) AR040010A1 (el)
AT (1) ATE329912T1 (el)
AU (1) AU2003242542B2 (el)
BR (1) BR0311177A (el)
CA (1) CA2485926C (el)
CL (1) CL2004001251A1 (el)
CY (1) CY1105159T1 (el)
DE (1) DE60306152T2 (el)
DK (1) DK1506190T3 (el)
ES (1) ES2265581T3 (el)
HK (1) HK1080845A1 (el)
HR (1) HRP20041060B1 (el)
IL (1) IL164922A (el)
MA (1) MA27117A1 (el)
ME (1) MEP76708A (el)
MX (1) MXPA04011253A (el)
NO (1) NO329605B1 (el)
NZ (1) NZ536310A (el)
PL (1) PL211340B1 (el)
PT (1) PT1506190E (el)
RS (1) RS51200B (el)
RU (1) RU2317294C2 (el)
SI (1) SI1506190T1 (el)
TN (1) TNSN04224A1 (el)
WO (1) WO2003097637A1 (el)
ZA (1) ZA200408789B (el)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
GB0218876D0 (en) * 2002-08-13 2002-09-25 Merck Sharp & Dohme Therapeutic agents
CN100579579C (zh) * 2002-10-01 2010-01-13 诺华疫苗和诊断公司 抗癌及抗感染性疾病组合物及其使用方法
KR101289923B1 (ko) * 2005-05-03 2013-07-25 메르크 파텐트 게엠베하 유기 전계발광 장치 및 그에 사용되는 붕산 및 보린산유도체
US20090054392A1 (en) * 2007-08-20 2009-02-26 Wyeth Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
JP5315710B2 (ja) * 2008-02-07 2013-10-16 セントラル硝子株式会社 1−ブロモ−3−フルオロ−5−ジフルオロメチルベンゼンの製造方法
DE102008015033A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
EP2254580A1 (en) * 2008-03-27 2010-12-01 EVOTEC Neurosciences GmbH Methods for treating disorders using nmda nr2b-subtype selective antagonist
GEP20146004B (en) 2009-02-05 2014-01-10 Takeda Pharmaceuticals Co Pyridazinone compounds
JP5785548B2 (ja) 2010-08-04 2015-09-30 武田薬品工業株式会社 縮合複素環化合物
WO2012019106A2 (en) * 2010-08-06 2012-02-09 Board Of Regents Of The University Of Nebraska Positive and negative modulators of nmda receptors
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
US9981950B2 (en) * 2014-08-15 2018-05-29 Janssen Pharmaceuticals, Inc. Triazoles as NR2B receptor inhibitors
SG11201806750WA (en) 2016-02-10 2018-09-27 Janssen Pharmaceutica Nv Substituted 1,2,3-triazoles as nr2b-selective nmda modulators
EP3416959B1 (en) 2016-02-18 2021-05-12 Syngenta Participations AG Pesticidally active pyrazole derivatives
WO2017158151A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2017158147A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途
WO2018119374A1 (en) 2016-12-22 2018-06-28 Cadent Therapeutics Nmda receptor modulators and uses thereof
US11008302B2 (en) 2018-04-04 2021-05-18 Janssen Pharmaceutica Nv Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators
FI3830092T3 (fi) 2018-08-03 2023-07-21 Novartis Ag Heteroaromaattiset NMDA-reseptorimodulaattorit ja niiden käytöt
EP3983074A1 (en) 2019-06-14 2022-04-20 Janssen Pharmaceutica NV Pyridine carbamates and their use as glun2b receptor modulators
EP3983072A1 (en) 2019-06-14 2022-04-20 Janssen Pharmaceutica NV Pyrazine carbamates and their use as glun2b receptor modulators
AU2020292994A1 (en) 2019-06-14 2022-01-06 Janssen Pharmaceutica Nv Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators
US11161846B2 (en) 2019-06-14 2021-11-02 Janssen Pharmaceutica Nv Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators
EP3983075A1 (en) 2019-06-14 2022-04-20 Janssen Pharmaceutica NV Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators
CA3143276A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators
CN114478210A (zh) * 2022-02-26 2022-05-13 江苏壹药新材料有限公司 一种7-氯萘-2-甲醛的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU717140B2 (en) 1996-03-08 2000-03-16 F. Hoffmann-La Roche Ag Use of 4-phenyl-3,6-dihydro-2H-pyridyl derivatives as NMDA receptor subtype blockers
CA2220649C (en) 1996-12-03 2007-02-13 F. Hoffmann-La Roche Ag 4-hydroxy-piperidine derivatives
US6015824A (en) * 1998-02-10 2000-01-18 Hoffmann-La Roche Ag Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders
TWI254043B (en) 1999-06-08 2006-05-01 Hoffmann La Roche Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor
ATE257827T1 (de) 1999-07-21 2004-01-15 Hoffmann La Roche Triazolderivate
US6339093B1 (en) 1999-10-08 2002-01-15 Hoffmann-La Roche Inc. Isoquinoline derivatives
CA2404464C (en) 2000-04-20 2008-03-11 F. Hoffmann-La Roche Ag Pyrrolidine and piperidine derivatives and their use for the treatment of neurodegenerative disorders
US6432985B2 (en) 2000-04-25 2002-08-13 Hoffmann-La Roche Inc. Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists
AU2001296994A1 (en) 2000-10-06 2002-04-15 Regents Of The University Of California Nmda receptor channel blocker with neuroprotective activity
CA2381630A1 (en) 2001-04-23 2002-10-23 Leonard Theodore Meltzer Method for preventing dyskinesias
DE10120159A1 (de) 2001-04-25 2002-10-31 Merck Patent Gmbh NMDA-Antagonisten und NMDA-Agonisten zur Behandlung von Suchterkrankungen
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives

Also Published As

Publication number Publication date
EP1506190B1 (en) 2006-06-14
NO20044666L (no) 2004-12-15
MEP76708A (en) 2011-12-20
DK1506190T3 (da) 2006-10-16
RS98504A (en) 2006-12-15
PL211340B1 (pl) 2012-05-31
BR0311177A (pt) 2005-03-15
TNSN04224A1 (fr) 2007-03-12
NO329605B1 (no) 2010-11-22
AU2003242542B2 (en) 2008-10-16
ATE329912T1 (de) 2006-07-15
ES2265581T3 (es) 2007-02-16
ZA200408789B (en) 2005-12-28
CL2004001251A1 (es) 2005-04-22
RU2317294C2 (ru) 2008-02-20
KR100632868B1 (ko) 2006-10-13
US7005432B2 (en) 2006-02-28
PT1506190E (pt) 2006-11-30
DE60306152T2 (de) 2007-04-26
AR040010A1 (es) 2005-03-09
PL374224A1 (en) 2005-10-03
CN1312151C (zh) 2007-04-25
JP4267569B2 (ja) 2009-05-27
HRP20041060A2 (en) 2005-06-30
MXPA04011253A (es) 2005-01-25
CN1653062A (zh) 2005-08-10
IL164922A0 (en) 2005-12-18
EP1506190A1 (en) 2005-02-16
SI1506190T1 (sl) 2006-10-31
IL164922A (en) 2012-01-31
HRP20041060B1 (en) 2012-11-30
CA2485926A1 (en) 2003-11-27
AU2003242542A1 (en) 2003-12-02
CA2485926C (en) 2009-11-24
KR20040106558A (ko) 2004-12-17
RU2004136979A (ru) 2005-07-10
JP2005532326A (ja) 2005-10-27
MA27117A1 (fr) 2004-12-20
DE60306152D1 (de) 2006-07-27
RS51200B (sr) 2010-12-31
WO2003097637A1 (en) 2003-11-27
US20030229096A1 (en) 2003-12-11
HK1080845A1 (en) 2006-05-04
NZ536310A (en) 2007-08-31

Similar Documents

Publication Publication Date Title
CY1105159T1 (el) (ιμιδαζολ-1-υλο-μεθυλο)-πυριδαζινη ως παρεμποδιστης υποδοχεα νμda
MA31593B1 (fr) Derives de 2-aza-bicyclo[3.3.0]octane
CY1118862T1 (el) Νεα δικυκλικη ετεροκυκλικη ενωση
DE60336850D1 (en) Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
CY1105631T1 (el) Υποκατεστημενα παραγωγα καρβοστυριλης ως αγωνιστες 5-ητ1α υποτυπου δεκτη
MA31000B1 (fr) Derives 2-aza-bicyclo[3.1.0]hexane
UY30426A1 (es) Derivados sustituidos del 3-(4-metoxi-fenil)-3h-isoindol-1-ilamina trifluoroacetado, sus sales o solvatos farmaceuticamente aceptables, formulaciones farmacéuticas y aplicaciones.
MX2009010024A (es) Nuevo compuesto de adenina.
EA200200248A1 (ru) Производные 3(5)-аминопиразола, способ их получения и их применение в качестве противоопухолевых средств
ECSP066760A (es) Derivado de 4-oxopirimidina de anillos condensados
MA32558B1 (fr) Composes organiques
TW200718692A (en) Dihydrobenzofuran derivatives and uses thereof
WO2009146024A8 (en) Etomidate analogues with improved pharmacokinetic and pharmacodynamic properties
DE602008005238D1 (de) Bisphenol Monoester
NZ596653A (en) Total synthesis of salinosporamide a and analogs thereof
BRPI0606639A2 (pt) novo processo para a preparação de indóis substituìdos
MY152557A (en) 3-aminocyclopentanecarboxamides as chemokine receptor modulators
EP2000473A4 (en) TREHALOSE COMPOUND AND PHARMACEUTICAL PRODUCT COMPRISING THE SAME
EA200800149A1 (ru) 4,5-диарилпиррольные производные, способ их получения и применение в терапии
BR0316702A (pt) xprocesso para preparação de (s)-pantoprazol
PT1204658E (pt) Agonistas benzofurilpiperazina de serotonina
EA200970497A1 (ru) Производные пиррола, их получение и их применение в терапии
TR200103532T2 (tr) Etansulfonil-piperadin türevleri
BR0113348A (pt) Pró-drogas para ligantes de receptores de nmda
TW200801016A (en) Thienopyridine-2-carboxamide derivatives